CLEAN : Health workers receive first jabs of controversial Covaxin in India

The transcript discusses the efficacy of vaccines, personal vaccination choices, and the challenges faced due to limited availability of certain vaccines like COVID Shield and Pfizer. It highlights the importance of phase three clinical trial data and the expectations from ongoing trials involving thousands of volunteers. The speaker expresses hope for positive results and effective vaccine applications in the future.

What is the main concern the speaker has about the vaccine?

• The availability of the vaccine

• The side effects of the vaccine

• The efficacy of the vaccine

• The cost of the vaccine

Why does the speaker prefer vaccines like COVID Shield or Pfizer?

• They have fewer side effects

• They are more widely available

• They have phase three clinical trial data

• They are cheaper

What limitation does the speaker face regarding vaccine choice?

• Geographical constraints

• Lack of information

• High cost

• Limited supply

How many volunteers are involved in the phase three trials mentioned by the speaker?

• 15,000

• 10,000

• 30,000

• 22,500

What is the speaker's hope regarding the phase three trial results?

• That they will be negative

• That they will show good efficacy

• That they will be inconclusive

• That they will be delayed